ERBB2 and prostate cancer: In fact, there is a large number of studies using TMAs with one 0.6 mm cores that confirm the known prognostic relevance of virtually all previously established clinically useful biomarkers, for instance, between alterations of HER2 [54] or p53 [55] and survival in breast cancer, between vimentin expression and prognosis in kidney cancer [56], and even between heterogeneous markers such as Ki67 labeling index and prognosis in urinary bladder cancer [57], breast cancer [58] and prostate cancer [53].